U toku su istraživanja njegove potencijalne primene kao neuroprotektivnog leka u borbi protiv Alchajmerove bolesti, kao i mogućnosti nootropne upotrebe.[5] Jedna od kliničkih studija u faze III za Alcheimerovu bolesti je utvrdila da on nije koristan. Tri druge studije su u toku.[6] Kliničko ispitivanje za Hantingtonovu bolest nije bilo uspešno.[7]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Matveeva IA (July 1983). „Action of dimebon on histamine receptors” (Russian). Farmakologiia i Toksikologiia46 (4): 27–29. PMID6225678.
↑Shevtsova EF, Kireeva EG, Bachurin SO (2005). „Mitochondria as the target for neuroprotectors” (Russian). Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (9): 13–17. PMID16250325.
↑Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO (November 2001). „Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels”. Bulletin of Experimental Biology and Medicine132 (5): 1079–1083. DOI:10.1023/A:1017972709652. PMID11865327.
↑Grigorev VV, Dranyi OA, Bachurin SO (November 2003). „Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons”. Bull Exp Biol Med136 (5): 474–477. DOI:10.1023/B:BEBM.0000017097.75818.14. PMID14968164.
↑Gankina EM, Porodenko NV, Kondratenko TI, Severin ES, Kaminka ME, Mashkovskiĭ MD (1993). „[The effect of antihistaminic preparations on the binding of labelled mepyramine, ketanserin and quinuclidinyl benzilate in the rat brain]” (Russian). Eksperimental'naia I Klinicheskaia Farmakologiia56 (1): 22–4. PMID8100727.